Cytokinetics CEO puts nail in takeout rumour coffin, says buyer walked away
2024-06-05
并购临床3期
After months of speculation – and investor hopes – that cardiovascular drug developer Cytokinetics would be bought up by a major pharma for billions, the biotech seemingly put an end to that possibility last month by doubling down on a financing arrangement with Royalty Pharma. Now, CEO Robert Blum has shed more light on why a takeout deal never materialised in what he said will be the company’s “final statements on this matter.”
Acquisition rumours first surfaced in December ahead of a readout for the highly anticipated Phase III SEQUOIA-HCM trial evaluating Cytokinetics' cardiac myosin inhibitor aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy. Then in January, a report that Novartis was close to finalising a deal to buy the biotech further sent investors salivating, though days later, the Swiss pharma was said to have shied away.
Detailed results for aficamten presented in May suggested the treatment could be a safer alternative to Bristol Myers Squibb’s approved therapy Camzyos (mavacamten), reigniting rumours once again. For more, see Spotlight On: Has Phase III win put Cytokinetics back on the M&A chopping block?
However, Cytokinetics later signed a deal with Royalty Pharma worth up to $1 billion, a financing that Mizuho Securities analysts said “furthers the stock from the potential takeout thesis.”
No actionable proposal
Blum seemingly confirmed that Cytokinetics had indeed attracted the interest of several companies, saying Wednesday at the Jefferies Global Healthcare Conference that “throughout 2023, Cytokinetics engaged in business development discussions with potential strategic partners.”
Additionally, he said that Cytokinetics was approached by a third party “leading up to and after our late December 2023 disclosure of top-line results from SEQUOIA-HCM… regarding its interest in an acquisition for all of our company.”
Blum said that while the company proposed terms “that we believed were going to be mutually acceptable… the third party did not move forward with an acquisition.”
“If there had been an actionable proposal in the best interests of shareholders, it would have received support of our board and would have been executed with support of management,” Blum concluded. He also seemed to address the takeout rumour mill, adding that “it is unfortunate that private confidential discussions leaked.”
Investors seemed to react positively to Blum’s candour, as Cytokinetics’ stock jumped about 10% on Wednesday.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。